StemRIM

StemRIM Operating Cash Flow

The Operating Cash Flow of StemRIM (4599.T) as of Nov 6, 2026 is -1.61 B JPY. In the previous year, Operating Cash Flow was -1.41 B JPY — a change of 13.81% (lower).

Operating Cash Flow

-1.61 BJPY

YoY

13.81%

Last updated:

Operating Cash Flow of StemRIM is 2026 -1.61 B JPY. Operating Cash Flow of StemRIM was 2025 -1.41 B JPY. It decreases by 13.81% lower compared to the previous year.

The StemRIM Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2019
-777.79 M JPY
Jan 1, 2020
575.41 M JPY
Jan 1, 2021
-519.65 M JPY
Jan 1, 2022
-1.40 B JPY
Jan 1, 2023
1.14 B JPY
Jan 1, 2024
-1.88 B JPY
Jan 1, 2025
-1.41 B JPY
Jan 1, 2026
-1.61 B JPY
The StemRIM Operating Cash Flow history
YEAROperating Cash FlowYoY
-1.61 BJPY+13.81%
-1.41 BJPY-24.81%
-1.88 BJPY-265.72%
1.14 BJPY-180.83%
-1.40 BJPY+170.29%
-519.65 MJPY-190.31%
575.41 MJPY-173.98%
-777.79 MJPY+198.03%
-260.98 MJPY-8.54%
-285.35 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM, Inc. develops and researches regeneration-inducing medicine based on a new action mechanism to promote functional regeneration and healing of damaged biological tissue. The company's main product is stem cell regeneration-inducing medicine, which delivers therapeutic effects similar to regenerative medicine without requiring living cells or tissues. StemRIM's primary customers are medical institutions and healthcare providers seeking advanced treatment options for tissue repair and regeneration. The company generates revenue through the sale of its stem cell regeneration-inducing medicine to these healthcare segments. StemRIM focuses on research and development of medicines that can restore lost function in biological tissue caused by injury or illness. The firm's product line centers around its stem cell regeneration-inducing medicine, which eliminates the need for using living cells in treatment. This innovative approach targets medical professionals and institutions looking for efficient regenerative solutions. StemRIM's business model relies on selling its patented medicine to healthcare providers for clinical applications. The company's revenue streams come from the commercialization of its stem cell regeneration-inducing medicine, which is designed to provide regenerative therapy without cell-based treatments. StemRIM's target market includes hospitals and medical facilities that require advanced regenerative treatments for patients with tissue damage. The firm's research and development efforts are centered on creating medicines that can promote healing through a novel mechanism, differentiating their product from traditional regenerative medicine approaches. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Operating Cash Flow of StemRIM is -1.61 B JPY in 2026.

Operating Cash Flow of StemRIM changed from -1.41 B JPY to -1.61 B JPY, representing a 13.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow StemRIM since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's StemRIM historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — StemRIM

All Key Metrics — StemRIM